KREBS BIOCHEMICALS & INDUSTRIES
|
KREBS BIOCHEMICALS & INDUSTRIES Last 5 Year Financial Ratios History
[Standalone]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | -9.15 | -11.45 | -20.65 | -14.45 | -16.04 |
| CEPS(Rs) | -6.01 | -8.41 | -17.73 | -11.84 | -13.44 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | -55.29 | -46.13 | -34.83 | -23.91 | -18.14 |
| Tax Rate(%) | - | - | - | - | - |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | -17.30 | -30.27 | -56.94 | -32.73 | -55.53 |
| EBIT Margin(%) | -29.83 | -41.66 | -65.55 | -41.12 | -68.45 |
| Pre Tax Margin(%) | -39.13 | -47.36 | -74.58 | -52.81 | -86.41 |
| PAT Margin (%) | -39.13 | -47.36 | -74.58 | -52.81 | -86.41 |
| Cash Profit Margin (%) | -25.71 | -34.78 | -64.03 | -43.27 | -72.41 |
| Performance Ratios | |||||
| ROA(%) | -11.17 | -13.54 | -25.51 | -19.36 | -20.91 |
| ROE(%) | - | - | - | - | - |
| ROCE(%) | -18.99 | -28.59 | -57.38 | -40.28 | -56.96 |
| Asset Turnover(x) | 0.29 | 0.29 | 0.34 | 0.37 | 0.24 |
| Sales/Fixed Asset(x) | 0.16 | 0.18 | 0.22 | 0.21 | 0.14 |
| Working Capital/Sales(x) | -1.14 | -1.58 | -1.40 | -2.01 | -1.38 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 6.10 | 5.67 | 4.60 | 4.69 | 7.15 |
| Receivable days | 8.79 | 4.91 | 3.60 | 1.71 | 17.00 |
| Inventory Days | 78.69 | 131.30 | 128.88 | 107.38 | 130.87 |
| Payable days | 948.90 | 378.02 | 263.51 | 305.42 | 507.31 |
| Valuation Parameters | |||||
| PER(x) | - | - | - | - | - |
| PCE(x) | -10.15 | -6.71 | -8.09 | -7.50 | -6.09 |
| Price/Book(x) | -1.10 | -1.22 | -4.12 | -3.72 | -4.52 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 6.45 | 5.85 | 7.57 | 5.30 | 6.39 |
| EV/Core EBITDA(x) | -39.30 | -20.11 | -13.77 | -16.79 | -11.74 |
| EV/EBIT(x) | -21.62 | -14.04 | -11.55 | -12.90 | -9.33 |
| EV/CE(x) | 4.37 | 3.63 | 2.38 | 1.79 | 1.60 |
| M Cap / Sales | 2.61 | 2.33 | 5.18 | 3.25 | 4.41 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -3.29 | -12.68 | 11.18 | 60.72 | -30.04 |
| Core EBITDA Growth(%) | 45.43 | 53.83 | -93.68 | 6.79 | -92.84 |
| EBIT Growth(%) | 30.76 | 44.50 | -77.25 | 3.45 | -66.64 |
| PAT Growth(%) | 20.10 | 44.55 | -57.01 | 1.78 | -44.28 |
| EPS Growth(%) | 20.10 | 44.55 | -42.89 | 9.89 | -33.30 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | -1.62 | -1.84 | -1.91 | -2.37 | -2.03 |
| Current Ratio(x) | 0.28 | 0.33 | 0.45 | 0.44 | 0.44 |
| Quick Ratio(x) | 0.12 | 0.08 | 0.13 | 0.10 | 0.09 |
| Interest Cover(x) | -3.21 | -7.30 | -7.26 | -3.52 | -3.81 |
| Total Debt/Mcap(x) | 1.47 | 1.51 | 0.46 | 0.64 | 0.45 |
Compare Financial Ratios of peers of KREBS BIOCHEMICALS & INDUSTRIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KREBS BIOCHEMICALS & INDUSTRIES | ₹216.0 Cr | 1.9% | 5.3% | 38.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹420,699.0 Cr | 0.6% | -4.6% | 20.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹162,584.0 Cr | 9.8% | 4.5% | 64.7% | Stock Analytics | |
| CIPLA | ₹116,022.0 Cr | -2.9% | -3.9% | 1.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,463.0 Cr | 0.9% | -10.4% | 0.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹98,434.8 Cr | 0.9% | -0.3% | 27.9% | Stock Analytics | |
KREBS BIOCHEMICALS & INDUSTRIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KREBS BIOCHEMICALS & INDUSTRIES | 1.9% |
5.3% |
38.8% |
| SENSEX | 2% |
0.1% |
8.6% |
You may also like the below Video Courses
